Montelukast as monotherapy in children with mild persistent asthma

Wei Fong Wu, Jiunn Ren Wu, Zen Kong Dai, Chin Wen Tsai, Tzu Chun Tsai, Chia Chun Chen, Chueh Yuan Yang

研究成果: 雜誌貢獻文章

4 引文 斯高帕斯(Scopus)

摘要

The cysteinyl leukotrienes cause bronchoconstriction, increased mucus production and airway inflammation, three major features of asthma. Several randomized controlled trials have shown the efficacy of leukotriene receptor antagonists for improving asthma outcomes. The drug is favored for treating childhood asthma, where poor compliance with inhalation therapy is a therapeutic challenge. To assess the effectiveness of Montelukast in asthmatic children under real-life conditions, a prospective, single-arm, multicenter, open-label observational study was performed on asthmatic children 2 to 14 years old with a history of physician-diagnosed mild persistent asthma. Montelukast was given once daily for 12 consecutive weeks. By the end a significant improvement of the daytime asthma symptom score, nighttime asthma score, peak expiratory flow rate (PEFR) and mean score of the investigators' global evaluation was noted (p < 0.05). These results suggest that montelukast is an effective monotherapy controller in children with mild persistent asthma.

原文英語
頁(從 - 到)173-180
頁數8
期刊Asian Pacific Journal of Allergy and Immunology
27
發行號4
出版狀態已發佈 - 十二月 1 2009
對外發佈Yes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

指紋 深入研究「Montelukast as monotherapy in children with mild persistent asthma」主題。共同形成了獨特的指紋。

  • 引用此

    Wu, W. F., Wu, J. R., Dai, Z. K., Tsai, C. W., Tsai, T. C., Chen, C. C., & Yang, C. Y. (2009). Montelukast as monotherapy in children with mild persistent asthma. Asian Pacific Journal of Allergy and Immunology, 27(4), 173-180.